Antonio Ribeiro-Oliveira Jr
Overview
Explore the profile of Antonio Ribeiro-Oliveira Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan J, Ribeiro-Oliveira Jr A, Houchard A, Dennen S, Liu Y, Naga S, et al.
Adv Ther
. 2025 Mar;
PMID: 40080241
Introduction: This study investigated the burden of comorbidities and concomitant non-cancer medications and their cost in patients with neuroendocrine tumors (NETs). Methods: Adults with gastroenteropancreatic (GEP)-NETs and lung-NETs, with or...
2.
Loughrey P, Mothojakan N, Iacovazzo D, Arni A, Aflorei E, Arnaldi G, et al.
Eur J Endocrinol
. 2025 Mar;
PMID: 40070360
Objective: Heterozygous germline loss-of-function variants in AIP are associated with young-onset growth hormone and/or prolactin-secreting pituitary tumours. However, the pathogenic role of the c.911G>A; p.(Arg304Gln) (R304Q) AIP variant has been...
3.
Vilar L, Naves L, Martins M, Ribeiro-Oliveira Jr A
Best Pract Res Clin Endocrinol Metab
. 2024 Mar;
38(3):101878.
PMID: 38519400
A small proportion of the patients with acromegaly present with apparently normal basal GH levels and suppressible GH levels despite increased IGF-1 levels, a pattern called micromegaly by some authors....
4.
OToole D, Kunz P, Webb S, Goldstein G, Khawaja S, McDonnell M, et al.
Adv Ther
. 2024 Mar;
41(6):2531-2533.
PMID: 38480663
No abstract available.
5.
Fleseriu M, Barkan A, Brue T, Duquesne E, Houchard A, Del Pilar Schneider M, et al.
J Endocr Soc
. 2023 Sep;
7(10):bvad104.
PMID: 37705695
Context: Treatment of acromegaly is multimodal for many patients, and medical treatments include somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and growth hormone receptor antagonists (GHRAs). However, recent real-world evidence...
6.
OToole D, Kunz P, Webb S, Goldstein G, Khawaja S, McDonnell M, et al.
Adv Ther
. 2022 Dec;
40(2):671-690.
PMID: 36502449
Introduction: Real-world data evaluating patients' injection experiences using the latest devices/formulations of the long-acting (LA) somatostatin analogs (SSAs) lanreotide Autogel/Depot (LAN; Somatuline®) and octreotide LA release (OCT; Sandostatin®) are limited....
7.
Boguszewski C, Korbonits M, Artignan A, Garcia A, Houchard A, Ribeiro-Oliveira Jr A, et al.
Endocrine
. 2022 Nov;
79(3):527-536.
PMID: 36369434
Purpose: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with...
8.
Fleseriu M, Barkan A, Del Pilar Schneider M, Darhi Y, de Pierrefeu A, Ribeiro-Oliveira Jr A, et al.
Pituitary
. 2022 Jan;
25(2):296-307.
PMID: 34973139
Purpose: Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications...
9.
Almeida M, Freire C, Nunes M, Santana Soares B, Barbosa M, Giannetti A, et al.
Growth Horm IGF Res
. 2021 Dec;
62:101442.
PMID: 34952478
Objective: Cardiovascular (CV) disease is still a major cause of excessive morbidity and mortality in patients with active acromegaly, which may be attributed to a high prevalence of associated pro-atherosclerotic...
10.
Heaney A, de Oliveira R, Bizzi M, Correa R, Pereira M, Simao Mol S, et al.
F1000Res
. 2021 Oct;
9:1399.
PMID: 34621522
The Nottingham Health Profile (NHP) is a generic measure of perceived distress that has been used widely as an outcome measure in clinical practice and trials. The availability of two...